Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.authorwosidKAYA, Emin/W-2951-2017
dc.contributor.authorBerber, Ilhami
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorNizam, Ilknur
dc.contributor.authorKoroglu, Mustafa
dc.contributor.authorKaya, Emin
dc.contributor.authorKuku, Irfan
dc.contributor.authorBag, Harika Gozukara
dc.date.accessioned2024-08-04T20:41:18Z
dc.date.available2024-08-04T20:41:18Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHigh-dose chemotherapy (HDC) applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with malignant lymphoma. At present, there is a limited number of studies which compare toxicity and efficacy of various high-dose regimens applied in the treatment of malignant lymphoma. For this reason, the aim of this study was to investigate the efficacy and toxicity of BuCyE (busulfan, cyclophosphamide and etoposide) and BEAM (carmustine, etoposide, cytarabine and melphalan) preparative regimens in the patients with malignant lymphoma scheduled for autologous stem cell transplantation. Between November, 2010 and April, 2015, 42 patients with relapsed or refractory malignant lymphoma who underwent autologous stem cell transplantation following BEAM (n=11) and BuCyE (n=31) preparative regimens were analyzed at Bone Marrow Transplantation Unit of TurgutOzal Medicine Center in Turkey. The groups were compared in terms of patient characteristics, hematopoietic engraftment time, toxicity profiles and survival. No significant differences were detected between the groups with regard to age, gender distribution, international prognostic index, ASCT indications, disease status at the time of ASCT and type of lymphoma (P>0.05). Median number of infused CD34+ cells/kg, neutrophil and platelet engraftment statuses of BuCyE and BEAM groups were found to be similar (P>0.05). More patients in BuCyE group developed mucositis and nausea, but this difference was not statistically significant (P>0.05). A similar statistically insignificant difference was seen in that infectious complications occurred more commonly in BEAM group (P>0.05). Overall survival and event-free survival rates were not significantly different between the groups (P>0.05). BuCyE is a conditioning regimen which can be effectively used as an alternative to BEAM in the patients with malignant lymphoma undergoing ASCT. Moreover, toxicity rates of both regimens are similar. In order to comprehend the effect of each HDC regimen, further evidence-based data obtained from the studies involving larger sample sizes are required.en_US
dc.identifier.endpage16314en_US
dc.identifier.issn1940-5901
dc.identifier.issue9en_US
dc.identifier.pmid26629149en_US
dc.identifier.scopus2-s2.0-84946552740en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage16308en_US
dc.identifier.urihttps://hdl.handle.net/11616/97044
dc.identifier.volume8en_US
dc.identifier.wosWOS:000365273300088en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBuCyEen_US
dc.subjectBEAMen_US
dc.subjectautologous transplantationen_US
dc.subjectlymphomaen_US
dc.titleCan BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu